不眠症の世界市場レポート 2024年

不眠症の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.2%の年間複合成長率（CAGR）で60億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、世界の健康危機の影響、睡眠衛生に対する意識の高まり、メンタルヘルスとウェルネスの重視の高まり、睡眠の健康に対する政府の取り組み、と睡眠に対する社会的決定要因の影響に起因すると考えられます。予測期間中に予想される主要動向としては、睡眠モニタリングのためのデジタルヘルスソリューションの採用、不眠症に対する認知行動療法の導入、睡眠相談のための遠隔医療の利用、プライマリケアへの睡眠健康の統合、新規研究に関する進行中の調査が挙げられます。 不眠症治療の治療対象。

不眠症市場は、仕事関連のストレスの急増により成長が見込まれています。仕事関連のストレスとは、仕事の要求、プレッシャー、労働者の資源、能力、知識の不一致から生じる有害な感情的と身体的反応を指します。仕事のストレスは、不眠症などの健康不良につながる可能性があります。 不眠症の重症度によって治療アプローチが決定され、薬物療法や認知行動療法が含まれる場合があります。 不眠症市場では、仕事関連のストレスの増加により売上が増加しています。たとえば、2021年 10月に米国心理学会が実施した調査では、米国従業員1,500人のうち約59%が仕事関連のストレスを経験していることが明らかになりました。さらに、2022年 11月の米国労働統計局によると、2021年には負傷の合計率が増加し、報告された負傷は2020年と比較して6.3%増加しました。この仕事関連のストレスの急増は、不眠症市場の重要な推進力です。

不眠症市場の成長は、慢性疾患の有病率の増加によっても促進されると予想されます。 3か月以上続き、時間の経過とともに悪化する慢性疾患は、不眠症などの併存疾患を引き起こすことがよくあります。心血管障害、糖尿病、慢性疼痛などの慢性疾患を持つ人は、睡眠関連の問題を頻繁に経験します。慢性疾患の有病率の上昇により、効果的な不眠症治療法と管理戦略に対する需要が生まれ、市場の成長に貢献しています。 2023年1月の国立バイオテクノロジー情報センターによると、世界の慢性疾患患者の数は、2020年の7,152万2,000人から2050年までに1億4,266万人に達すると予測されています。したがって、慢性疾患の有病率の増加は、慢性疾患を引き起こす重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の不眠症市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の不眠症市場規模実績と成長率、2018～2023年
• 世界の不眠症市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の不眠症市場、治療タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 非薬物療法
• 薬物療法
• 世界の不眠症市場、薬剤クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 抗うつ薬
• メラトニンアンタゴニスト
• ベンゾジアゼピン系
• 非ベンゾジアゼピン系薬剤
• オレキシンアンタゴニスト
• その他
• 世界の不眠症市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 非経口
• その他
• 世界の不眠症市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域と国の分析

• 世界の不眠症市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の不眠症市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 不眠症市場の競合情勢
• 不眠症市場の企業プロファイル
  • Pfizer Inc.
  • Merck &Co Inc.
  • Sanofi SA
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Limited

第31章 その他の大手と革新的な企業

• Koninklijke Philips NV
• Viatris Inc.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Eisai Co.Ltd.
• UCLA Health Insomnia Clinic
• Jazz Pharmaceuticals PLC
• Aurobindo Pharma Limited
• Purdue Pharma LP
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Zydus Lifesciences Limited
• Lupin Limited
• Mallinckrodt Pharmaceuticals Plc.
• Fisher &Paykel Healthcare Corporation Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Insomnia is a sleep disorder characterized by difficulties in falling or staying asleep. Depending on the duration of symptoms, insomnia can be categorized as either short-term (acute) or long-term (chronic). Various treatments, including drugs, digital therapeutics, and devices, are employed to address insomnia conditions.

The main therapy types for insomnia encompass non-pharmacological therapy and pharmacological therapy. Non-pharmacological interventions (NPI) or non-pharmacological therapies involve non-chemical interventions performed on and benefiting the patient, such as light therapy and exercise. The various drug classes utilized in pharmacological therapy include anti-depressants, melatonin antagonists, benzodiazepines, non-benzodiazepines, orexin antagonists, and others. These drugs are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The insomnia market research report is one of a series of new reports from The Business Research Company that provides insomnia market statistics, including insomnia industry global market size, regional shares, competitors with an insomnia market share, detailed insomnia market segments, market trends, and opportunities, and any further data you may need to thrive in the insomnia industry. This insomnia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insomnia market size has grown strongly in recent years. It will grow from $4.72 billion in 2023 to $4.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth observed in the historical period can be attributed to factors such as increased stress levels, the prevalence of mental health conditions, shift work and irregular work hours, increased awareness and diagnosis of insomnia, and high consumption of stimulants.

The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the impact of the global health crisis, an increasing awareness of sleep hygiene, a growing emphasis on mental health and wellness, government initiatives for sleep health, and the influence of social determinants on sleep. Major trends expected in the forecast period include the adoption of digital health solutions for sleep monitoring, the implementation of cognitive-behavioral therapy for insomnia, the use of telehealth for sleep consultations, the integration of sleep health into primary care, and ongoing research on novel therapeutic targets for insomnia treatment.

The insomnia market is expected to experience growth due to the surge in work-related stress. Work-related stress refers to harmful emotional and physical responses resulting from a mismatch between work demands, pressures, and the worker's resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. The severity of insomnia determines the treatment approach, which may involve drug or cognitive-behavioral therapies. The insomnia market is witnessing increased sales due to the rise in work-related stress. For instance, a survey by the American Psychology Association in October 2021 revealed that about 59% of 1,500 US employees were experiencing work-related stress. Additionally, according to the US Bureau of Labor Statistics in November 2022, the total rate of injuries increased in 2021, with reported injuries rising by 6.3% compared to 2020. This surge in work-related stress is a significant driver of the insomnia market.

The growth of the insomnia market is also expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting for three months or more and worsening over time, often lead to comorbid conditions such as insomnia. Individuals with chronic conditions such as cardiovascular disorders, diabetes, and chronic pain frequently experience sleep-related issues. The rising prevalence of chronic diseases creates a demand for effective insomnia treatments and management strategies, contributing to the growth of the market. According to the National Center for Biotechnology Information in January 2023, the global number of people with chronic diseases is projected to reach 142.66 million by 2050, up from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is a significant factor driving the growth of the insomnia market.

A key trend in the insomnia market is the adoption of product innovation. Major companies in the insomnia therapeutics market are developing innovative treatments to maintain their market positions. For example, WELT, a Korea-based medical device company, received approval for its digital insomnia treatment device, WELT-I, in April 2023. WELT-I is designed to correct behavioral, psychological, and cognitive factors contributing to insomnia. It delivers treatment based on cognitive behavioral therapy (CBT), a first-line treatment for insomnia. The device, classified as software as a medical device (SaMD), analyzes sleep patterns, intervenes in patient behavior, and delivers personalized relaxation therapy for eight weeks to improve sleep quality and reduce tension and anxiety.

Major companies in the insomnia market are introducing new products, such as zaleplon-based insomnia drugs, to gain a competitive edge. Zaleplon, a non-benzodiazepine sedative-hypnotic medication, is used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon is known for its rapid onset of action, short half-life, and minimal impact on daily activities. The launch of Zaledeep Cap. aims to provide a new and effective treatment option for individuals suffering from insomnia in response to the increasing cases in modern society.

In August 2022, ResMed, a US-based medical equipment company, acquired Mementor to strengthen its sleep portfolio in Germany. This acquisition included somnio, a digital solution for insomnia, Germany's first and only permanently approved digital health application (DiGA) in sleep medicine. Somnio focuses on improving sleep in insomnia patients, addressing the care gap, and providing alternatives to prevailing drug therapy. Mementor, a Germany-based developer of digital insomnia therapy solutions, contributes to ResMed's overall commitment to enhancing sleep-related healthcare.

Major companies operating in the insomnia market report are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.

North America was the largest region in the insomnia market in 2023. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the insomnia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insomnia Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insomnia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insomnia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insomnia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Therapy Type: Non-Pharmacological Therapy; Pharmacological Therapy
• 2) By Drug Class: Anti-Depressants; Melatonin Antagonist; Benzodiazepines; Nonbenzodiazepines; Orexin Antagonist; Other Drug Classes
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc.; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Insomnia Market Characteristics

3. Insomnia Market Trends And Strategies

4. Insomnia Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Insomnia Market Size and Growth

• 5.1. Global Insomnia Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Insomnia Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Insomnia Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Insomnia Market Segmentation

• 6.1. Global Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Non-Pharmacological Therapy
• Pharmacological Therapy
• 6.2. Global Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Anti-Depressants
• Melatonin Antagonist
• Benzodiazepines
• Nonbenzodiazepines
• Orexin Antagonist
• Other Drug Classes
• 6.3. Global Insomnia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.4. Global Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Insomnia Market Regional And Country Analysis

• 7.1. Global Insomnia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Insomnia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Insomnia Market

• 8.1. Asia-Pacific Insomnia Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Insomnia Market

• 9.1. China Insomnia Market Overview
• 9.2. China Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Insomnia Market

• 10.1. India Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Insomnia Market

• 11.1. Japan Insomnia Market Overview
• 11.2. Japan Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Insomnia Market

• 12.1. Australia Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Insomnia Market

• 13.1. Indonesia Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Insomnia Market

• 14.1. South Korea Insomnia Market Overview
• 14.2. South Korea Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Insomnia Market

• 15.1. Western Europe Insomnia Market Overview
• 15.2. Western Europe Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Insomnia Market

• 16.1. UK Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Insomnia Market

• 17.1. Germany Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Insomnia Market

• 18.1. France Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Insomnia Market

• 19.1. Italy Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Insomnia Market

• 20.1. Spain Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Insomnia Market

• 21.1. Eastern Europe Insomnia Market Overview
• 21.2. Eastern Europe Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Insomnia Market

• 22.1. Russia Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Insomnia Market

• 23.1. North America Insomnia Market Overview
• 23.2. North America Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Insomnia Market

• 24.1. USA Insomnia Market Overview
• 24.2. USA Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Insomnia Market

• 25.1. Canada Insomnia Market Overview
• 25.2. Canada Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Insomnia Market

• 26.1. South America Insomnia Market Overview
• 26.2. South America Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Insomnia Market

• 27.1. Brazil Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Insomnia Market

• 28.1. Middle East Insomnia Market Overview
• 28.2. Middle East Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Insomnia Market

• 29.1. Africa Insomnia Market Overview
• 29.2. Africa Insomnia Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Insomnia Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Insomnia Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Insomnia Market Competitive Landscape And Company Profiles

• 30.1. Insomnia Market Competitive Landscape
• 30.2. Insomnia Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Sanofi S.A.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GlaxoSmithKline plc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Takeda Pharmaceutical Company Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Insomnia Market Other Major And Innovative Companies

• 31.1. Koninklijke Philips N.V.
• 31.2. Viatris Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. Eisai Co.Ltd.
• 31.6. UCLA Health Insomnia Clinic
• 31.7. Jazz Pharmaceuticals PLC
• 31.8. Aurobindo Pharma Limited
• 31.9. Purdue Pharma LP
• 31.10. Cipla Inc.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Zydus Lifesciences Limited
• 31.13. Lupin Limited
• 31.14. Mallinckrodt Pharmaceuticals Plc.
• 31.15. Fisher & Paykel Healthcare Corporation Limited

32. Global Insomnia Market Competitive Benchmarking

33. Global Insomnia Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Insomnia Market

35. Insomnia Market Future Outlook and Potential Analysis

• 35.1 Insomnia Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Insomnia Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Insomnia Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer